抗体导向疗法：迈向用于皮肤T细胞淋巴瘤的持久且耐受性良好的治疗平台。
Antibody-Directed Therapies: Toward a Durable and Tolerable Treatment Platform for CTCL.
作者信息
Khan Shaheer, Sawas Ahmed
机构信息
Department of Medicine, Center for Lymphoid Malignancies, Columbia University Medical Center, The New York Presbyterian Hospital, College of Physician and Surgeons, New York, NY, United States.
出版信息
Front Oncol. 2019 Jul 30;9:645. doi: 10.3389/fonc.2019.00645. eCollection 2019.
Abstract
Cutaneous T-cell lymphomas (CTCL) are a rare group of heterogeneous disorders characterized by cutaneous involvement of monoclonal T-lymphocytes. Although indolent at early stages, CTCL can confer significant morbidity, and mortality when advanced. There is an unmet need for tolerable and durable treatments with antibodies recently gaining promise. Here we review approved systemic therapies and discuss select antibodies in development.
摘要
皮肤T细胞淋巴瘤（CTCL）是一组罕见的异质性疾病，其特征是单克隆T淋巴细胞累及皮肤。尽管CTCL在早期进展缓慢，但进展期可导致严重的发病率和死亡率。目前对耐受性良好且持久的治疗方法仍有需求，而抗体治疗最近显示出前景。本文综述了已获批的全身治疗方法，并讨论了正在研发的特定抗体。
相似文献
1
Antibody-Directed Therapies: Toward a Durable and Tolerable Treatment Platform for CTCL.抗体导向疗法：迈向用于皮肤T细胞淋巴瘤的持久且耐受性良好的治疗平台。
Front Oncol. 2019 Jul 30;9:645. doi: 10.3389/fonc.2019.00645. eCollection 2019.
2
Emerging drugs for the treatment of cutaneous T-cell lymphoma.新型治疗皮肤 T 细胞淋巴瘤的药物。
Expert Opin Emerg Drugs. 2022 Mar;27(1):45-54. doi: 10.1080/14728214.2022.2049233. Epub 2022 Mar 8.
3
Existing and Emerging Therapies for Cutaneous T-Cell Lymphoma.现有的和新兴的皮肤 T 细胞淋巴瘤治疗方法。
J Cutan Med Surg. 2019 May/Jun;23(3):319-327. doi: 10.1177/1203475419840629. Epub 2019 Apr 3.
4
New Targeted Treatments for Cutaneous T-cell Lymphomas.皮肤T细胞淋巴瘤的新型靶向治疗方法
Indian J Dermatol. 2017 Mar-Apr;62(2):142-145. doi: 10.4103/ijd.IJD_73_17.
5
Systemic therapy of cutaneous T-cell lymphoma (CTCL).皮肤T细胞淋巴瘤（CTCL）的全身治疗。
Chin Clin Oncol. 2019 Feb;8(1):10. doi: 10.21037/cco.2019.01.02.
6
Antibody-Based Therapies for Cutaneous T-Cell Lymphoma.基于抗体的皮肤 T 细胞淋巴瘤治疗方法。
Am J Clin Dermatol. 2019 Feb;20(1):115-122. doi: 10.1007/s40257-018-0402-5.
7
Experimental treatment strategies in primary cutaneous T-cell lymphomas.原发性皮肤T细胞淋巴瘤的实验性治疗策略
Curr Opin Oncol. 2016 Mar;28(2):166-71. doi: 10.1097/CCO.0000000000000272.
8
Brentuximab vedotin in T-cell lymphoma.本妥昔单抗维达汀治疗 T 细胞淋巴瘤。
Expert Rev Hematol. 2019 Jan;12(1):5-19. doi: 10.1080/17474086.2019.1558399. Epub 2018 Dec 18.
9
Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update.治疗皮肤 T 细胞淋巴瘤（CTCL）的研究性药物：最新进展。
Expert Opin Investig Drugs. 2019 Sep;28(9):799-809. doi: 10.1080/13543784.2019.1654995. Epub 2019 Aug 18.
10
Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome.晚期蕈样霉菌病和赛泽里综合征的系统性治疗选择。
Curr Oncol Rep. 2018 Mar 23;20(4):32. doi: 10.1007/s11912-018-0678-x.
引用本文的文献
1
Janus kinase inhibitors - a role for the treatment of cutaneous T-cell lymphomas?Janus激酶抑制剂——在皮肤T细胞淋巴瘤治疗中的作用？
Oncol Rev. 2025 Aug 11;19:1482866. doi: 10.3389/or.2025.1482866. eCollection 2025.
2
Macrophages in inflammatory skin diseases and skin tumors.炎症性皮肤病和皮肤肿瘤中的巨噬细胞。
Front Immunol. 2024 Dec 5;15:1430825. doi: 10.3389/fimmu.2024.1430825. eCollection 2024.
3
Emerging drugs for the treatment of cutaneous T-cell lymphoma.新型治疗皮肤 T 细胞淋巴瘤的药物。
Expert Opin Emerg Drugs. 2022 Mar;27(1):45-54. doi: 10.1080/14728214.2022.2049233. Epub 2022 Mar 8.
4
Combination of Resminostat with Ruxolitinib Exerts Antitumor Effects in the Chick Embryo Chorioallantoic Membrane Model for Cutaneous T Cell Lymphoma.瑞司美诺司他与芦可替尼联合用药在皮肤T细胞淋巴瘤鸡胚绒毛尿囊膜模型中发挥抗肿瘤作用。
Cancers (Basel). 2022 Feb 20;14(4):1070. doi: 10.3390/cancers14041070.
5
PEG10 amplification at 7q21.3 potentiates large-cell transformation in cutaneous T-cell lymphoma.PEG10 扩增在 7q21.3 促进皮肤 T 细胞淋巴瘤的大细胞转化。
Blood. 2022 Jan 27;139(4):554-571. doi: 10.1182/blood.2021012091.
6
Mycosis fungoides and Sézary syndrome.蕈样肉芽肿和赛泽里综合征。
J Dtsch Dermatol Ges. 2021 Sep;19(9):1307-1334. doi: 10.1111/ddg.14610.
本文引用的文献
1
Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma.PD-1 抑制剂帕博利珠单抗治疗复发或难治性成熟 T 细胞淋巴瘤的 II 期研究。
Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):356-364.e3. doi: 10.1016/j.clml.2019.03.022. Epub 2019 Apr 3.
2
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.莫格利珠单抗对比伏立诺他治疗既往治疗的皮肤 T 细胞淋巴瘤（MAVORIC）：一项国际性、开放性标签、随机、对照的 3 期临床试验。
Lancet Oncol. 2018 Sep;19(9):1192-1204. doi: 10.1016/S1470-2045(18)30379-6. Epub 2018 Aug 9.
3
IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma.IPH4102，一种针对免疫受体分子 KIR3DL2 的单克隆抗体，用于治疗皮肤 T 细胞淋巴瘤。
Expert Opin Investig Drugs. 2018 Aug;27(8):691-697. doi: 10.1080/13543784.2018.1498081. Epub 2018 Jul 17.
4
E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma: A phase I study.E7777用于复发/难治性外周和皮肤T细胞淋巴瘤日本患者的I期研究。
Cancer Sci. 2018 Mar;109(3):794-802. doi: 10.1111/cas.13513. Epub 2018 Feb 26.
5
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.本妥昔单抗维达妥或医师选择治疗 CD30 阳性皮肤 T 细胞淋巴瘤（ALCANZA）：一项国际性、开放性标签、随机、3 期、多中心试验。
Lancet. 2017 Aug 5;390(10094):555-566. doi: 10.1016/S0140-6736(17)31266-7. Epub 2017 Jun 7.
6
Targeting CD47: the achievements and concerns of current studies on cancer immunotherapy.靶向CD47：癌症免疫治疗当前研究的成果与担忧
J Thorac Dis. 2017 Feb;9(2):E168-E174. doi: 10.21037/jtd.2017.02.30.
7
The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.CD47-SIRPα信号轴作为癌症中的一种固有免疫检查点。
Immunol Rev. 2017 Mar;276(1):145-164. doi: 10.1111/imr.12527.
8
TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding.TTI-621（SIRPαFc）：一种阻断 CD47 的固有免疫检查点抑制剂，具有广泛的抗肿瘤活性和最小的红细胞结合。
Clin Cancer Res. 2017 Feb 15;23(4):1068-1079. doi: 10.1158/1078-0432.CCR-16-1700. Epub 2016 Nov 17.
9
2016 US lymphoid malignancy statistics by World Health Organization subtypes.2016年按世界卫生组织亚型分类的美国淋巴系统恶性肿瘤统计数据。
CA Cancer J Clin. 2016 Nov 12;66(6):443-459. doi: 10.3322/caac.21357. Epub 2016 Sep 12.
10
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.纳武利尤单抗治疗复发或难治性血液系统恶性肿瘤患者：Ib期研究的初步结果
J Clin Oncol. 2016 Aug 10;34(23):2698-704. doi: 10.1200/JCO.2015.65.9789. Epub 2016 Jun 6.
Zotero 插件